OMEROS CORP: directors' dealings · United States · SEC (Form 4)

About OMEROS CORP

Omeros Corp. is a U.S.-based biopharmaceutical company listed on the Nasdaq under the ticker OMER. The company is headquartered in Seattle, Washington, United States. Founded in 1994, Omeros has built its business around discovering, developing, and in some cases commercializing first-in-class small-molecule and protein therapeutics. Its profile is that of a specialty biotech with both clinical-stage assets and an emerging commercial footprint, which makes it meaningfully different from a purely pre-revenue development company. ([omeros.com](https://www.omeros.com/about-omeros/?utm_source=openai)) Omeros’ core therapeutic focus spans complement-mediated diseases, immunologic disorders, certain cancers, and addictive or compulsive disorders. Its pipeline includes narsoplimab, an investigational lectin-pathway complement inhibitor, and OMS527, a PDE7 inhibitor being developed for cocaine use disorder. The company also describes a growing portfolio of recombinant antibodies and other oncology-related programs. This diversified scientific approach gives Omeros multiple shots on goal, but it also reflects the high clinical and regulatory risk profile typical of specialty biotech investing. ([investor.omeros.com](https://investor.omeros.com/about-us/default.aspx?utm_source=openai)) Commercially, Omeros has begun to generate product revenue. In January 2026, the company launched YARTEMLEA in the U.S. market, and in its first-quarter 2026 update it reported gross product sales of $11.1 million and net sales of $9.9 million. For investors, this is an important milestone because it suggests the company is not relying solely on future pipeline optionality; it is starting to build an operating base around marketed products as well. ([investor.omeros.com](https://investor.omeros.com/news/news-details/2026/Omeros-Corporation-Reports-First-Quarter-2026-Financial-Results/default.aspx?utm_source=openai)) From a competitive standpoint, Omeros operates in highly specialized therapeutic niches where scientific differentiation, patent protection, and clinical data are the main sources of advantage. If late-stage data and regulatory outcomes are positive, the company’s orphan and specialty indications could support significant value creation. However, the stock remains exposed to substantial development risk, capital needs, and concentration risk across a limited number of lead assets. Recent financing activity, including a balance-sheet strengthening transaction in 2024 and a $22 million registered direct offering in 2025, underscores the capital-intensive nature of the business. ([investor.omeros.com](https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-further-strengthens-its-balance-sheet-through?utm_source=openai)) For French-speaking investors in France, Belgium, and Switzerland, Omeros should be viewed as a health-care/pharma name with a speculative but potentially asymmetric profile. It combines a U.S. Nasdaq listing, a Seattle headquarters, a research-driven pipeline, and an emerging commercial product base. Recent company disclosures and SEC Form 4 insider-filing activity suggest ongoing capital management and insider-trading monitoring remain relevant parts of the investment case. ([investor.omeros.com](https://investor.omeros.com/static-files/d2b387a5-961a-4757-bf4c-bcca55b1ab45?utm_source=openai))